Canaccord Genuity reiterates a 'Hold' on Arena Pharmaceuticals (ARNA); Lorcaserin CR Provides Only Very Dim Light At The End of Long Tunnel
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Hold' on Arena Pharmaceuticals (Nasdaq: ARNA), price target lowered to $1.
Canaccord analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
